Analysts: Biogen’s Drug Could Beat Projections and 3 More Research Notes to Explore

Biogen (NASDAQ:BIIB): RBC Capital is expecting that sales for Biogen’s Tecfidera drug will beat expectations, and that the company could raise its guidance. RBC keeps an Outperform rating on the shares.

BIIB

Schlumberger Limited (NYSE:SLB): Susquehanna raised its price target to $96 from $86 on Schlumberger, citing expectations of continued better-than-expected revenue growth, with margin expansion to come during the second half of 2013. It rates the shares at Positive.

SLB

Corning (NYSE:GLW): Sterne Agee sees the recent weakness in Corning shares, which come as a result of slowing Chinese TV sales, as a buying opportunity, and anticipates that gross margins will improve through the year as glass pricing declines moderate. The firm keeps a Buy rating on Corning.

GLW

Broadcom (NASDAQ:BRCM): Barclays says that its recent GS4 mini-i9195 and Galaxy Mega 6.3-i9205 tear-downs confirm its recent bearish statements, noting further share loss across nearly all OEMs, and not only Samsung. The firm rates the shares at Underweight.

BRCM

Don’t Miss: Gulf of Mexico Is Hot for Oil Again.

More from The Cheat Sheet